Ventyx Biosciences (VTYX)
(Real Time Quote from BATS)
$2.15 USD
-0.09 (-4.02%)
Updated Aug 2, 2024 10:54 AM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VTYX 2.15 -0.09(-4.02%)
Will VTYX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VTYX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VTYX
What Makes Ventyx Biosciences (VTYX) a New Buy Stock
Down -86.57% in 4 Weeks, Here's Why Ventyx Biosciences, Inc. (VTYX) Looks Ripe for a Turnaround
VTYX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ventyx (VTYX) Down Despite Positive Ulcerative Colitis Study Data
Take the Zacks Approach to Beat the Market: Uber, Baidu, AssetMark in Focus
Recent Price Trend in Ventyx Biosciences, Inc. (VTYX) is Your Friend, Here's Why
Other News for VTYX
Ventyx Biosciences: Hold Rating Affirmed Amid Clinical and Strategic Setbacks
Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn?s Disease
Ventyx Biosciences falls after trial for Crohn’s disease treatment did not meet main goal
Ventyx Biosciences announces reuslts from Phase 2 trial of VTX958
Ventyx falls 19% to $2.39 after Crohn's disease trial misses endpoint